CHRD

Across TCGA pan-cancer cohorts, CHRD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHRD data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CHRD mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CHRD expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where CHRD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.897	1.000	.032	20	view →
PDAC	OS	Quartile	All	0.653	0.378	.015	9	view →
LUAD	OS	Tertile	III,IV	0.669	1.000	.024	5	view →
UCEC	OS	Tertile	II,III,IV	0.532	1.000	.042	4	view →
CCRCC	DFS	Median	III,IV	0.112	0.777	.014	4	view →
LSCC	OS	Median	All	0.927	0.841	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHRD–HNSC (OS)

Open the HNSC breakdown →